Review of the Effects of Polysaccharides on Brain Function is Published
Mechanisms that might explain the cognitive benefits of Mannatechs glyconutrients and other polysaccharides are explored
COPPELL, Texas--(BUSINESS WIRE)-- Mannatech, Incorporated (NASDAQ: MTEX), the leading innovator and provider of nutritional supplements based on Real Food Technology® solutions, recently announced the publication of a comprehensive literature review reporting the effects of polysaccharides on brain function. Dr. Erika Nelson, a neuroscientist, and her colleagues reviewed controlled studies assessing various roles of exogenous saccharide compounds and polysaccharide-rich extracts on brain function, with a significant focus on benefits derived from oral intake. Her review includes a discussion of five randomized, double-blind, placebo-controlled clinical trials that indicate that Ambrotose® complex, a Mannatech (MTEX) product, positively impacts well-being, memory, cognitive function and mood in healthy adults.* Numerous preclinical studies were also identified that indicate various polysaccharides can modify behavior, enhance synaptic plasticity and provide neuroprotective effects.
Mannatech has consistently demonstrated a strong commitment to evaluating the impact of oral polysaccharide compounds on human health, said Dr. Robert Sinnott, CEO and Chief Science Officer at Mannatech. In 2010, we published a reviewwhich has been of great interest to the scientific communitywhich consolidated the extant literature reporting significant impacts of oral polysaccharides on immune function. Today, we are once again pleased to offer an important consolidation of the literature investigating the impact of oral polysaccharides on brain health and function. This literature review both clarifies the current state of the science in this area and suggests appropriate avenues for future research that will help us better understand the benefits of these important compounds.
Dr. Nelson earned her BS in Genetics from the University of Kansas in Lawrence and went on to obtain her PhD in Neuroscience at the University of Texas Southwestern Medical Center in Dallas. She has published a number of papers on neurodevelopmental disorders and brain epigenetics. A candidate for a Masters of Business Administration at the University of Texas at Dallas, Dr. Nelson is also a consultant for Mannatech. Co-authors of the review include Dr. Robert Sinnott; Dr. Talitha Best, a scientist with dual appointments at the University of South Australia, Adelaide, and Swinburne University of Technology, Victoria, Australia; and Jane Ramberg, Director of Product Substantiation at Mannatech.
Individuals interested in Mannatechs products or exploring its business opportunity are encouraged to learn more at Mannatech.com.
Mannatech, Incorporated, develops high-quality health, weight and fitness, and skin care products that are based on the solid foundation of nutritional science and development standards. Mannatech is dedicated to its platform of Social Entrepreneurship based on the foundation of promoting, aiding and optimizing nutrition where it is needed most around the world. Mannatechs proprietary products are available through independent sales Associates around the globe including the United States, Canada, South Africa, Australia, New Zealand, Austria, Denmark, Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan, Taiwan, Singapore, Estonia, Finland, the Republic of Ireland, Czech Republic, the Republic of Korea, Mexico and Namibia. For more information, visit Mannatech.com.
Please note: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as believe, intend or other similar words or the negative of such terminology. Similarly, descriptions of Mannatechs objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatechs inability to attract and retain Associates and Members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.
*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Current link to publication: http://www.ingentaconnect.com/content/maney/nns/pre-prints/1476830512Y.0000000004
Brett Duncan, 972-471-7367
Source: Mannatech, IncorporatedCopyright Business Wire 2012